Hemispherian

Hemispherian is an innovative pharmaceutical company focused on developing novel small-molecule drugs (GLIX). The company’s lead compound, GLIX1, is in the late preclinical development stage for the treatment of glioblastoma multiforme, a deadly cancer of the central nervous system and a leading cause of death in pediatric diseases. Hemispherian is also dedicated to developing a complementary diagnostic tool to support patient selection for optimal treatment response to GLIX1.